Department of Neurology, Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, D532, 33520, Tampere, Finland.
Department of Neurosciences and Rehabilitation, Tampere University Hospital, Tampere, Finland.
Sci Rep. 2021 Jul 2;11(1):13765. doi: 10.1038/s41598-021-93265-x.
The aim of this study was to evaluate the effects of deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) on systemic inflammatory responses in patients with drug-resistant epilepsy (DRE). Twenty-two Finnish patients with ANT-DBS implantation were enrolled in this pilot study. Changes in plasma interleukin-6 (IL-6) and interleukin-10 (IL-10) levels were examined using generalized estimating equation models at seven time points (before DBS surgery and 1, 2, 3, 6, 9 and 12 months after implantation). In the whole group, the IL-6/IL-10 ratio decreased significantly over time following ANT-DBS, while the decrease in IL-6 levels and increase in IL-10 levels were not significant. In the responder and nonresponder groups, IL-6 levels remained unchanged during the follow-up. Responders had significantly lower pre-DBS IL-10 levels before the ANT-DBS treatment than nonresponders, but the levels significantly increased over time after the treatment. In addition, responders had a higher pre-DBS IL-6/IL-10 ratio than nonresponders, and the ratio decreased for both groups after treatment, but the decrease did not reach the level of statistical significance. The rate of decrease in the ratio per month tended to be higher in responders than in nonresponders. These results may highlight the anti-inflammatory properties of ANT-DBS treatment associated with its therapeutic effectiveness in patients with DRE. Additional studies are essential to evaluate the potential of the proinflammatory cytokine IL-6, the anti-inflammatory cytokine IL-10, and their ratio as biomarkers to evaluate the therapeutic response to DBS treatment, which could facilitate treatment optimization.
本研究旨在评估丘脑前核深部脑刺激（ANT-DBS）对耐药性癫痫（DRE）患者全身炎症反应的影响。本研究纳入了 22 例接受 ANT-DBS 植入术的芬兰患者。使用广义估计方程模型在七个时间点（DBS 手术前和植入后 1、2、3、6、9 和 12 个月）检测血浆白细胞介素-6（IL-6）和白细胞介素-10（IL-10）水平的变化。在整个组中，ANT-DBS 后 IL-6/IL-10 比值随时间显著降低，而 IL-6 水平的降低和 IL-10 水平的升高并不显著。在应答者和无应答者组中，IL-6 水平在随访期间保持不变。与无应答者相比，应答者在接受 ANT-DBS 治疗前的预 DBS IL-10 水平显著降低，但在治疗后随时间显著升高。此外，应答者的预 DBS IL-6/IL-10 比值高于无应答者，且两组治疗后比值均降低，但未达到统计学意义。应答者的比值每月降低率高于无应答者。这些结果可能突出了 ANT-DBS 治疗的抗炎特性，与 DRE 患者的治疗效果相关。需要进一步的研究来评估促炎细胞因子 IL-6、抗炎细胞因子 IL-10 及其比值作为评估 DBS 治疗反应的潜在生物标志物的潜力，这可能有助于优化治疗。
